Previous work has revealed that the dual PI3K/mTOR inhibitor dactolisib (BEZ235) promotes AR signaling in a HER2/3 dependent manner in PTEN-deficient prostate cancer models, while AR-targeted therapy augments AKT signaling [181]. This evidence concerns the gene MTOR and prostate carcinoma.